• 1
    Chobanian AV, Bakris GL, Black HR, et al. National high blood pressure education program coordinating committee: seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:12061252.
  • 2
    The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007. Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:11051187.
  • 3
    Williams B, Poulter NR, Brown MJ, et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004–BHSIV. J Hum Hypertens. 2004;18:139185.
  • 4
    Mancia G, Laurent S, Agabati-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:21212158.
  • 5
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and epidemiology and Prevention. Circulation. 2007;115: 27612788.
  • 6
    Coleman TG, Hall JE. Systemic Hemodynamics and Regional Blood Flow Regulation. In: IzzoJLJr, BlackHR, SicaDA, eds. Hypertension Primer. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008.
  • 7
    Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326: 14271435.
  • 8
    Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study. JAMA. 1993;270:713724.
  • 9
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 10
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:17551762.
  • 11
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:9951003.
  • 12
    Dickerson JE, Hingorani AD, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353:20082013.
  • 13
    Mourad J, Waeber B, Zinnad F. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004;22:23792386.
  • 14
    Kotsis V, Stabouli S, Bouldin M, et al. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension. 2005;45:602607.
  • 15
    Izzo R, deSimone G, Chinali M, et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009;32:845850.
  • 16
    Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials. Am J Med. 2009;122:290300.
  • 17
    Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:243262.
  • 18
    Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep. 2002;4:343349.
  • 19
    Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29:972984.
  • 20
    Dunbar-Jacob. NHLBI Implementation Conference. 2009.
  • 21
    Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713719.
  • 22
    Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril hydrochlorothiazide combination. Arch Intern Med. 1994;154:737743.
  • 23
    Chrysant SG, Fagan T, Glazer R, et al. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996;5:1724.
  • 24
    Pool J, Cushman WC, Saini RK, et al. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens. 1997;10:117123.
  • 25
    Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol. 2008;51:519528.
  • 26
    Mackay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996;156:278285.
  • 27
    Ambrosioni E, Borghi C, Costa FV. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol. 1987;23(suppl 1):43S50.
  • 28
    Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352358.
  • 29
    Frishman WH, Ram CVS, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebocontrolled, parallel-group study. J Clin Pharmacol. 1995;35: 10601066.
  • 30
    Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563580.
  • 31
    Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587604.
  • 32
    Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol. 1997;79:431435.
  • 33
    Jamerson K, Weber MA, Bakris GL, et al; for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359:24172428.
  • 34
    Weber MA, Bakris GL, Dahlöf B, et al; for the ACCOMPLISH Investigators. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007;16:1319.
  • 35
    Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15471559.
  • 36
    Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial. Lancet. 2007;370:221229.
  • 37
    Salvetti A, Magagna A, Innocenti P, et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study. J Cardiovasc Pharmacol. 1991;17:332335.
  • 38
    Weir MR, Weber MA, Punzi HA, et al. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens. 1992;6: 133138.
  • 39
    Julius S, Kjeldsen SE, Weber M, et al; for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: theVALUE randomised trial. Lancet. 2004;363:20222031.
  • 40
    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:16841689.
  • 41
    Lindholm LH, Carlberg B, Samuelsson O. Should b blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:15451553.
  • 42
    Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24:21312141.
  • 43
    Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:17071713.
  • 44
    Frishman WH, Bryzinski BS, Coulson LR, et al. Amultifactorial trial design to assess combination therapy in hypertension. Arch Intern Med. 1994;154:14611468.
  • 45
    Bateman DN, Dean CR, Mucklow JC, et al. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol. 1979;7:357363.
  • 46
    Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens. 1994;8:283288.
  • 47
    Gradman AH. Drug Combinations. In: IzzoJLJr, BlackHR, SicaDA, eds. Hypertension Primer. 4th ed. Philadelphia PA: Lippincott, Williams, and Wilkins; 2008.
  • 48
    Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:18521857.
  • 49
    Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens. 2006;8:181186.
  • 50
    Myers MG. Hydrochlorothiazide with or without amiloride for hypertension in the elderly: a dose-titration study. Arch Intern Med. 1987;147:10261030.
  • 51
    Guerrero P, Fuchs FD, Moreria LM. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens. 2008;30: 553564.
  • 52
    Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30:418424.
  • 53
    Dahlöf B, Degl’ Innocenti A, Elmfeldt D, et al. Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. Am J Hypertens. 2005;18:13131319.
  • 54
    Frishman WH, Hainer JW, Sugg J; M-FACT Study Group. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release: results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). Am J Hypertens. Am J Hypertens. 2006;19: 388395.
  • 55
    Wing LMH, Chalmers JP, West MJ, et al. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. Clin Exp Hypertens. 1988;10:119133.
  • 56
    Mehta JL, Lopez LM. Rebound hypertension following abrupt cessation of clonidine and metoprolol. Treatment with labetalol. Arch Intern Med. 1987;147:389390.
  • 57
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:20492051.
  • 58
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290:28052816.
  • 59
    Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50:299305.
  • 60
    Weir M, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20:807815.
  • 61
    Jamerson K, Bakris GL, Dahlöf B, et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:8086.
  • 62
    Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646653.
  • 63
    Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2000; 9(suppl):26.
  • 64
    Egan BM. Fixed-dose combinations and hypertension control in community-based practices: application of the “keep-it-simple” principle. Hypertension. 2009;53:598599.
  • 65
    Carter BL, Bergus GR, Dawson JD. Evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens. 2008;10:260271.